Chronic Periodontitis
Conditions
Keywords
Leukotriene receptor antagonist, Chronic periodontitis, Scaling and root planing, C- reactive protein
Brief summary
The adjunctive use of Leukotriene Receptor Antagonist (Montelukast) along with scaling and root planing in patients with chronic periodontitis leads to host inflammatory response modulation and decrease in serum C reactive protein (CRP) levels. If proven this will open new vistas in treatment of chronic periodontitis.
Detailed description
A RCT was carried out to check the efficacy of Montelukast as an adjunct to scaling and root planing. The patients were randomised to either test group (SRP + Montelukast) and control group (SRP). Clinical parameters were assessed at baseline, 3 weeks and 6 weeks. Serum C-reactive protein levels were assessed at baseline, 3 weeks and 6 weeks.
Interventions
DRUGMontelukast
Patients in Montelukast Group were treated with scaling and root planing (SRP) along with Montelukast (Montair 10mg), 1 tablet twice daily for 3 weeks.
DRUGPlacebo
Patients in Placebo Group were treated with scaling and root planing (SRP) along with Placebo therapy, 1 tablet twice daily for 3 weeks.
Sponsors
Tatyasaheb Kore Dental College
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
30 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Patients within age group of 30 to 55 years. 2. Systemically healthy individuals. 3. Patients with chronic generalized periodontitis (moderate and severe) according to Center of Disease Control (CDC) working group, 2007 criteria
Exclusion criteria
1. Patients with systemic illnesses (i.e., diabetes mellitus, cancer, human immunodeficiency syndrome, bone metabolic diseases, or disorders that compromise wound healing, radiation, or immunosuppressive therapy), 2. Smoking, 3. Chronic alcoholics, 4. Pregnancy or lactation, 5. Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), steroids or antibiotics / antimicrobials within January 2012 to Jun 2013, 6. Confirmed or suspected intolerance to Montelukast, 7. Periodontal therapy done within the January 2012 to Jun 2013.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes from baseline in the serum C- reactive protein levels at 3 weeks and 6 weeks | baseline, 3 weeks and 6 weeks | The biochemical parameter of serum C- reactive protein levels were checked at baseline, 3 weeks and 6 weeks. Montelukast therapy was started at baseline and continued for 3 weeks in test group and the post treatment levels were further checked at 6 weeks (i.e. 3 weeks after stoppage of Montelukast.) the change in C- reactive protein levels was analysed. |
| Changes from baseline in the probing pocket depth at 3 weeks and 6 weeks | baseline, 3 weeks and 6 weeks. | The probing pocket depths were checked at baseline, 3 weeks and 6 weeks. Montelukast therapy was started at baseline and continued for 3 weeks in test group and the post treatment levels were further checked at 6 weeks (i.e. 3 weeks after stoppage of Montelukast.) The change in probing pocket depth was analysed. |
| Changes from baseline in the clinical attachment level at 3 weeks and 6 weeks. | baseline, 3 weeks and 6 weeks | The clinical attachment levels were checked at baseline, 3 weeks and 6 weeks. Montelukast therapy was started at baseline and continued for 3 weeks in test group and the post treatment levels were further checked at 6 weeks (i.e. 3 weeks after stoppage of Montelukast.) The change in clinical attachment levels was analysed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes from baseline in Gingival Index (GI) at 3 weeks and 6 weeks | baseline, 3 weeks and 6 weeks | changes from baseline in standard clinical parameter, GI were assessed at 3 weeks after starting therapy with Montelukast, then therapy was stopped and same changes were again assessed at 6 weeks from baseline. GI has a scoring criteria specified by Silness & Loe, 1963. |
| Changes from baseline in Sulcus Bleeding Index (SBI) at 3 weeks and 6 weeks | baseline, 3 weeks and 6 weeks | changes from baseline in standard clinical parameter, SBI were assessed at 3 weeks after starting therapy with Montelukast, then therapy was stopped and same changes were again assessed at 6 weeks from baseline. SBI has a scoring criteria specified by Muhleman (1971). |
| Changes from baseline in Plaque Index (PI) at 3 weeks and 6 weeks | baseline, 3 weeks and 6 weeks | changes from baseline in standard clinical parameter, PI were assessed at 3 weeks after starting therapy with Montelukast, then therapy was stopped and same changes were again assessed at 6 weeks from baseline. PI has a scoring criteria specified by Loe & Silness, 1964. |
| Changes from baseline in Oral Hygiene Index-Simplified (OHI-S) at 3 weeks and 6 weeks | baseline, 3 weeks and 6 weeks | changes from baseline in standard clinical parameter, OHI-S were assessed at 3 weeks after starting therapy with Montelukast, then therapy was stopped and same changes were again assessed at 6 weeks from baseline. OHI-S has a scoring criteria specified by Greene and Vermilion, 1964. |
Countries
India
Outcome results
None listed